Washington: A plant owned by Indian generic drugmaker Ranbaxy Laboratories falsified data and test results in approved and pending drug applications, US regulators said on Wednesday.
The Food and Drug Administration said it halted reviews of drug applications from Ranbaxy’s Paonta Sahib plant in India.
Agency officials said they were continuing to investigate to ensure the safety and effectiveness of drugs associated with the plant. They said they had not identified any health risks from Ranbaxy drugs currently on the market.
Patients should not stop taking Ranbaxy drugs but should consult a doctor if they are concerned, FDA officials said.
A Ranbaxy official could not immediately be reached for comment.
Japanese drugmaker Daiichi Sankyo holds a controlling stake in Ranbaxy.